Tern PLC Investor Presentations

RNS Number : 8270S

Tern PLC

10 January 2025

 

10 January 2025

 

Tern Plc

("Tern" or the "Company")

Investor Presentations

Tern Plc (AIM:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things ("IoT") technology businesses, is pleased to announce that following a well-attended online presentation and a Q&A session yesterday evening involving Tern's portfolio companies Device Authority, FundamentalVR, Talking Medicines and Vortex IQ (a Sure Valley Enterprise Capital Fund (SVV2) portfolio company), copies of the presentations from the participating companies can be found via the links below:

 

Device Authority presentation:  http://www.rns-pdf.londonstockexchange.com/rns/8270S_1-2025-1-9.pdf

FundamentalVR presentation:  http://www.rns-pdf.londonstockexchange.com/rns/8270S_2-2025-1-9.pdf

Talking Medicines presentation:  http://www.rns-pdf.londonstockexchange.com/rns/8270S_3-2025-1-9.pdf

Vortex IQ presentation:  http://www.rns-pdf.londonstockexchange.com/rns/8270S_4-2025-1-9.pdf

 

In addition a recording of the event is available to view on the Company's website at: https://www.ternplc.com/resources

 

Enquiries

 

Tern Plc Ian Ritchie (Chairman)	via IFC Advisory
Allenby Capital Limited (Nominated Adviser and Broker) Alex Brearley / Dan Dearden-Williams (Corporate Finance) Kelly Gardiner / Guy McDougall (Sales and Corporate Broking)	Tel: [phone]
IFC Advisory (Financial PR and IR) Tim Metcalfe Graham Herring Florence Chandler	Tel: [phone]

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCBLMMTMTBMTJA